---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-018249"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:44:34.100853+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monopar CFO Kim Tsuchimoto retiring; Karthik Radhakrishnan appointed successor

## Summary
- CFO Kim Tsuchimoto retires effective June 30, 2024 after 35+ years; remains on Board.
- Karthik Radhakrishnan appointed CFO, principal accounting and financial officer effective July 1, 2024.
- Radhakrishnan receives $384,800 annual salary, 35% target bonus, and options for 125,000 shares vesting over 4 years.
- Radhakrishnan has over 20 years experience; previously CFO of Opexa Therapeutics, founder of Titania Partners.

## SEC filing metadata
- accession: 0001437749-24-018249
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924018249/0001437749-24-018249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924018249/mnpr20240523c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-018249
- JSON: https://secwatch.observer/filing/0001437749-24-018249.json
- Plain text: https://secwatch.observer/filing/0001437749-24-018249.txt

## Key facts
- Executive change
  Kim R. Tsuchimoto departed as Chief Financial Officer at Monopar Therapeutics.
  - Action: retiring
  - Role: Chief Financial Officer
  source text: Effective June 30, 2024, after a career spanning more than 35 years, Kim R. Tsuchimoto, the Chief Financial Officer of Monopar Therapeutics Inc. (“Monopar” or the “Company”), will be retiring.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774924018249/0001437749-24-018249-index.htm
- Executive change
  Karthik Radhakrishnan was appointed as Chief Financial Officer at Monopar Therapeutics.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 23, 2024, the Company’s Board of Directors appointed, Karthik Radhakrishnan, age 53, to succeed Ms. Tsuchimoto as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774924018249/0001437749-24-018249-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.